Macquarie Group
CSTL icon

Macquarie Group’s Castle Biosciences CSTL Stock Holding History

Macquarie Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-850
Closed -$35K – 1843
2022
Q3 		$35K Sell
850
-476
-36% -$13.3K ﹤0.01% 2039
2022
Q2 		$29K Sell
1,326
-657,400
-100% -$15.3M ﹤0.01% 2196
2022
Q1 		$29.6K Buy
658,726
+2,174
+0.3% +$89.8K 0.02% 664
2021
Q4 		$28.1M Sell
656,552
-12,509
-2% -$654K 0.02% 669
2021
Q3 		$44.5M Buy
669,061
+178,844
+36% +$12.6M 0.04% 561
2021
Q2 		$35.9M Buy
490,217
+489,719
+98,337% +$32.3M 0.03% 635
2021
Q1 		$34K Buy
498
+278
+126% +$20.9K ﹤0.01% 2160
2020
Q4 		$15K Hold
220
– – ﹤0.01% 2260
2020
Q3 		$11K Hold
220
– – ﹤0.01% 2268
2020
Q2 		$8K Buy
+220
New +$7.52K ﹤0.01% 2311

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Macquarie Group's CSTL Position: Q4 2022 in Review

Macquarie Group sold out of Castle Biosciences (CSTL) in Q4 2022, closing a stake of 850 shares — an estimated $35K sold.

Macquarie Group first reported a position in CSTL in Q2 2020 and held it in 10 quarters. The position peaked at $44.5M in Q3 2021. 153 funds tracked by Wall St. Rank hold CSTL as of Q4 2022.

  • Macquarie Group reported no remaining Castle Biosciences position as of Q4 2022 after selling out during the quarter.
  • Macquarie Group sold 850 Castle Biosciences shares in Q4 2022, an estimated $35K.
  • Macquarie Group first reported a position in Castle Biosciences in Q2 2020 and held it in 10 quarters.
  • Macquarie Group's Castle Biosciences position peaked at $44.5M in Q3 2021.
  • 153 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.